{
    "clinical_study": {
        "@rank": "4764", 
        "acronym": "TESEC-07", 
        "arm_group": [
            {
                "arm_group_label": "0.1 \u00b5g C-Tb", 
                "arm_group_type": "Experimental", 
                "description": "The C-Tb agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme"
            }, 
            {
                "arm_group_label": "2 T.U Tuberculin PPD RT 23 SSI", 
                "arm_group_type": "Active Comparator", 
                "description": "The 2 T.U Tuberculin PPD RT 23 SSI agent is given alone to volunteers in the RIGHT or LEFT forearm according to a double blind randomisation scheme"
            }, 
            {
                "arm_group_label": "0.1 \u00b5g C-Tb / 2 T.U Tuberculin PPD", 
                "arm_group_type": "Experimental", 
                "description": "The C-Tb and 2 T.U Tuberculin PPD RT 23 SSI agents are given concomitantly to volunteers in the RIGHT and LEFT forearms according to a double blind randomisation scheme"
            }
        ], 
        "brief_summary": {
            "textblock": "A new, more specific skin test to detect tuberculosis has been developed by Statens Serum\n      Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a\n      positive test result will show as redness and/or induration at the injection site, while a\n      negative test will leave no reactions.\n\n      The aim of this study is to address if the size of induration and the sensitivity of C-Tb is\n      influenced by concomitant injections of C-Tb and Tuberculin. Furthermore, the intention is\n      to evaluate the safety of C-Tb when injected alone or concomitantly with Tuberculin."
        }, 
        "brief_title": "Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Tuberculosis", 
        "condition_browse": {
            "mesh_term": "Tuberculosis"
        }, 
        "detailed_description": {
            "textblock": "The TESEC-07 trial is a GCP double blind randomised controlled phase II/III trial\n      investigating if concomitant injections of the diagnostic agents C-Tb and 2 T.U Tuberculin\n      PPD RT 23 SSI affect the induration responses in combination with a safety assessment of\n      C-Tb. TESEC-07 is a multi-centre trial and will be conducted in South Africa in patients\n      recently diagnosed with TB comprising 360 HIV negative and 90 HIV positive adults allocated\n      to 3 trial groups.\n\n        -  A within group paired comparison of 0.1 \u03bcg/0.1 mL C-Tb and PPD RT 23 in 150 TB\n           patients. The C-Tb and PPD RT 23 agents are given concomitantly to each volunteer in\n           the RIGHT AND LEFT forearms according to a randomisation scheme.\n\n        -  A group of 150 TB patients will only receive the C-Tb agent randomised to either RIGHT\n           or LEFT forearm.\n\n        -  A group of 150 TB patients will only receive the reference agent PPD RT 23 randomised\n           to either RIGHT or LEFT forearm."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (HIV Negative patients):\n\n          -  Has signed an informed consent\n\n          -  Aged 18 to 65 years\n\n          -  Has been diagnosed with active pulmonary TB:\n\n               1. has a compatible clinical picture of TB according to South African guidelines\n                  with the intention to treat and 1 documented positive culture result or\n\n               2. has a compatible clinical picture of TB according to South African Guidelines\n                  with the intention to treat and 1 documented positive GeneXpert analysis\n\n          -  Is HIV negative confirmed by 2 two rapid tests\n\n          -  Is willing and likely to comply with the trial procedures\n\n          -  Is prepared to grant authorized persons access to their medical record\n\n        Inclusion Criteria (HIV Positive patients):\n\n          -  Has signed an informed consent\n\n          -  Aged 18-65 years\n\n          -  Has been diagnosed with active pulmonary TB:\n\n               1. has a compatible clinical picture of TB according to South African guidelines\n                  with the intention to treat and 1 documented positive culture result or\n\n               2. has a compatible clinical picture of TB according to South African Guidelines\n                  with the intention to treat and 1 documented positive GeneXpert analysis\n\n          -  Is HIV positive confirmed by:\n\n               1. 2 positive rapid tests  or\n\n               2. 1 positive rapid tests and an additional confirmatory ELISA\n\n          -  A CD4 count has been performed\n\n          -  Is willing and likely to comply with the trial procedures\n\n          -  Is prepared to grant authorized persons access to their medical records\n\n        Exclusion Criteria:\n\n          -  Has been in treatment for TB for more than 2 weeks\n\n          -  Has a known MDR/XDR-TB\n\n          -  Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion\n             (e.g. MMR, yellow fever, oral typhoid vaccines) except BCG vaccine\n\n          -  Has been tuberculin (TST) tested < 12 months prior to the day of inclusion\n\n          -  Is pregnant, breastfeeding or intending to get pregnant\n\n          -  Is a female of child bearing potential not willing to use effective barrier\n             (including spermicidal gel), hormonal or intrauterine contraceptive measures during\n             the trial period\n\n          -  Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's\n             disease, lymphoma, leukaemia, sarcoidosis)\n\n          -  Has a current skin condition which interferes with the reading of the skin tests e.g.\n             tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin\n             disease at or near the injection sites\n\n          -  Has a condition where blood drawings pose more than minimal risk for the patient,\n             such as haemophilia, other coagulation disorders, or significantly impaired venous\n             access\n\n          -  Currently participating in another clinical trial with an investigational or non\n             investigational drug or device, or has participated in another clinical trial within\n             the 3 months prior to dosing\n\n          -  Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10\n             antigens\n\n          -  Has a condition which in the opinion of the investigator is not suitable for\n             participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779102", 
            "org_study_id": "TESEC-07"
        }, 
        "intervention": [
            {
                "arm_group_label": "0.1 \u00b5g C-Tb", 
                "description": "C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme", 
                "intervention_name": "C-Tb", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "2 T.U Tuberculin PPD RT 23 SSI", 
                "description": "Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme", 
                "intervention_name": "Tuberculin PPD RT 23 SSI", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "0.1 \u00b5g C-Tb / 2 T.U Tuberculin PPD", 
                "description": "The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme", 
                "intervention_name": "C-Tb / Tuberculin PPD RT 23 SSI", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "contact": {
                    "email": "boylouw@mweb.co.za", 
                    "last_name": "Elizabeth Hellstrom", 
                    "phone": "+ 27 (0) 21 868 3990"
                }, 
                "facility": {
                    "address": {
                        "city": "Paarl", 
                        "country": "South Africa", 
                        "state": "Western Cape", 
                        "zip": "7626"
                    }, 
                    "name": "Be Part Yoluntu Centre"
                }, 
                "investigator": {
                    "last_name": "Elizabet Hellstrom, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Benoni", 
                        "country": "South Africa", 
                        "zip": "1501"
                    }, 
                    "name": "Worthwhile Clinical Trials"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "dr.zoja@task.org.za", 
                    "last_name": "Zoja Novelijc, MD", 
                    "phone": "+ 27 (0) 21 949 7751"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7530"
                    }, 
                    "name": "TASK, M2, Karl Bremer Hospital,"
                }, 
                "investigator": {
                    "last_name": "Zoja Novelijc, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "msiebert@ttctrials.co.za", 
                    "last_name": "M Siebert, MD", 
                    "phone": "+ 27 (0) 21 957 9400"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7530"
                    }, 
                    "name": "Tiervlei Trial Centre, Karl Bremer Hospital"
                }, 
                "investigator": {
                    "last_name": "M Siebert, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "keertan.dheda@uct.ac.za", 
                    "last_name": "Keertan Dheda, MD, Prof", 
                    "phone": "+ 27 (0) 21 404 7650"
                }, 
                "facility": {
                    "address": {
                        "city": "Cape Town", 
                        "country": "South Africa", 
                        "zip": "7925"
                    }, 
                    "name": "UCT Lung Institute"
                }, 
                "investigator": {
                    "last_name": "Keertan Dheda, MD, Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mashra@gctrials.co.za", 
                    "last_name": "M Gani, MD", 
                    "phone": "+ 27 (0) 41 404 0589"
                }, 
                "facility": {
                    "address": {
                        "city": "Port Elizabeth", 
                        "country": "South Africa", 
                        "zip": "6014"
                    }, 
                    "name": "Primecure Medicentre"
                }, 
                "investigator": {
                    "last_name": "M Gani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mookho@setshaba.org.za", 
                    "last_name": "M Malahleha, MD", 
                    "phone": "+ 27 (0) 12 799 2422"
                }, 
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "zip": "0152"
                    }, 
                    "name": "Setshaba Research Centre"
                }, 
                "investigator": {
                    "last_name": "M Malahleha, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "SBCRInv1@synexus-sa.co.za", 
                    "last_name": "Boitumelo Sebopa, MD", 
                    "phone": "+ 27 (0) 12 812 0469"
                }, 
                "facility": {
                    "address": {
                        "city": "Pretoria", 
                        "country": "South Africa", 
                        "zip": "0122"
                    }, 
                    "name": "Synexus Stanza Bopape Clinic"
                }, 
                "investigator": {
                    "last_name": "Boitumelo Sebopa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "South Africa"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II/III Trial Investigating if Concomitant Injections of the Diagnostic Agents C-Tb and 2 T.U Tuberculin PPD RT 23 SSI Affect the Induration Responses in Combination With a Safety Assessment of C-Tb", 
        "overall_contact": {
            "email": "keertan.dheda@uct.ac.za", 
            "last_name": "Keertan Dheda, MD, Prof", 
            "phone": "+ 27 (0) 21 404 7650"
        }, 
        "overall_contact_backup": {
            "email": "pnt@ssi.dk", 
            "last_name": "Pernille N Tingskov, BN, RN", 
            "phone": "+45 32688505"
        }, 
        "overall_official": [
            {
                "affiliation": "Statens Serum Institut", 
                "last_name": "Pernille N Tingskov, BN, RN", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "UCT Lung Institute, University of Cape Town", 
                "last_name": "Keertan Dheda, MD, Prof", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Africa: Medicines Control Council", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "To compare the size of induration of C-Tb and PPD RT 23 if injected alone or concomitantly in Tuberculosis infected patients (HIV positives and HIV negatives)", 
                "safety_issue": "No", 
                "time_frame": "Onset from the injection(s) to 28 days after the injections"
            }, 
            {
                "measure": "To assess if concomitant injections of C-Tb and PPD RT 23 influence the tests abilities to identify positive results of Tuberculosis in Tuberculosis infected patients", 
                "safety_issue": "No", 
                "time_frame": "Onset from the injection(s) to 28 days after the injections"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the in vitro QuantiFERON\u00aeTB Gold In Tube assay in blood collected immediately before application of the C-Tb skin test", 
                "safety_issue": "No", 
                "time_frame": "Onset from the injection(s) to 28 days after the injections"
            }, 
            {
                "measure": "To compare the C-Tb test's ability to identify positive results in Tuberculosis infected patients with the PPD RT 23 test", 
                "safety_issue": "No", 
                "time_frame": "Onset from the injection(s) to 28 days after the injections"
            }, 
            {
                "measure": "To assess the safety of C-Tb skin test by investigating laboratory safety parameters and assessing all adverse events (local and systemic) occurring within 28 days after administration of the C-Tb and/or PPD RT 23 tests", 
                "safety_issue": "Yes", 
                "time_frame": "Onset from the injection(s) to 28 days after the injections"
            }
        ], 
        "source": "Statens Serum Institut", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Statens Serum Institut", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}